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1. Introduction 
One of the challenging tasks in manufacturing process is to improve the 
bioavailability of poorly water-soluble drugs. In recent years, an increasing number of 
active agents posses low aqueous solubility. As a result, oral delivery of poorly water-
soluble drugs often results in low bioavailability. Various methods have been introduced 
to enhance the bioavailability of the poorly water-soluble drugs, which can be 
summarized in physical and chemical modifications. 
Among these methods, preparation of solid dispersion has become one of the 
most active areas of research in the pharmaceutical field to improve the bioavailability of 
poorly water-soluble drugs. This method involved the formation of eutectic mixtures of 
drugs with water-soluble carriers by melting of their physical mixture, which resulted in 
solubility enhancement. 
Numerous papers on various aspects of solid dispersion have been published and 
despite early promising results in laboratory scale, the commercial application of solid 
dispersion in dosage form design has been very limited. Problems limiting the 
commercial application of solid dispersion involve its method of preparation, 
reproducibility, its formulation into dosage forms, the scale up manufacturing processes, 
and the physical and chemical stability of drug and vehicle. 
Dropping method as a new possibility in preparation of solid dispersion helps to 
overcome some of the manufacturing difficulties. Dropping method facilitates the 
crystallization of different chemicals, is a new procedure for producing round particles 
from melted solid dispersions. Round particles produced by dropping method can be used 
directly as ready dosage form or it can be filled into capsules. Round particles can be 
processed further for coating if desired. This is a cost-effective method, which simplifies 
the production process by avoiding the pulverization, sifting, and compressibility 
difficulties encountered with the other melt methods. Dropping method a green 
technology, which avoids the use of harmful materials to our environment. 
 
2. Aims 
 The aim of this PhD work was to produce solid dispersion of poorly water-soluble 
drugs with the use of new pharmaceutical technology methods, which simplifies the 
process of production and scale up. For this purpose two sets of experiments were carried 
out using Levodopa and Meloxicam as poorly water-soluble drugs. Developing the new 
technology was with special regard to fast drug release from the product. 
The following objectives were set: 
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• The overview of the literature related to the subject; 
• Performing two sets of experiments with two different compounds (Levodopa and 
Meloxicam as poorly water-soluble drugs) to evaluate the new technology; 
• Investigation of the carriers, applicability and reproducibility of the new 
technology. 
At first set of experiments Levedopa were used to carry out the preformulation 
studies to investigate the applicability of the new technology. At second set Meloxicam 
were formulated by dropping method and wider investigations were applied for better 
understanding of the new technology. 
 
3. Materials and methods 
 
Materials 
• Levodopa (Dihydroxy-fenylanaline, melting range: 276-286 °C) one of the most 
effective active agents for the management of Parkinson’s disease were used as 
poorly water-soluble drug in preformulation studies. 
• Meloxicam (ME) (melting range: 258-261 °C) is an effective NSAID with poorly 
water-soluble characteristic. All other reagents and solvents were of analytical 
grade. 
• Polyethylene glycol (PEG) 4000 (melting range: 50-58 °C) was used as water-
soluble carrier for preparation of the solid dispersions. 
  The ratio of the drug-PEG 4000 mixtures at both sets was 1:3 respectively. 
 
Methods 
 
Conventional method 
 For the preparation of a Levodopa-PEG 4000 solid dispersion by conventional 
method, PEG 4000 was weighed and melted at 58 °C (± 1 °C) and a measured amount of 
Levodopa was added and stirred. After solidification at room temperature, sample was 
pulverized with use of a pestle and mortar and sieved through a 400-µm mesh. 60 mg of 
Levodopa-PEG 4000 powder (containing 15 mg of Levodopa and 45 mg of PEG 4000) 
was filled into a hard gelatin capsule (size no 2) for further investigations. 
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Direct capsule filling method 
 For the preparation of the Levodopa-PEG 4000 solid dispersion by direct capsule 
filling method, PEG 4000 was weighed and melted in a double-layered beaker at 58 °C (± 
1 °C) and a measured amount of Levodopa was added and stirred. The measured amounts 
of Levodopa and PEG 4000 corresponded to a drug - carrier ratio of 1:3. 60 mg of drug-
carrier mixture was filled directly into a hard gelatin capsule (size no 2) for further 
investigations. 
 
Preparation of physical mixture 
 For the preparation of a ME-PEG 4000 physical mixture, ME and PEG 4000 were 
weighed and mixed for 5 min with use of a pestle and mortar and sieved through a 400-
µm mesh. 60 mg of ME - PEG 4000 powder mixture (containing 15 mg of ME and 45 mg 
of PEG 4000) was filled into a hard gelatin capsule (size no 2) for further investigations. 
 
Tablet-making 
ME - PEG 4000 tablets were prepared with a Korsch EKO eccentric tablet 
machine (Emil Korsch Maschinenfabrik, Berlin, Germany). The compression tools were 
single, flat punches 10 mm in diameter, furnished with strain gauges. The physical 
mixture of ME - PEG 4000 was compressed at a pressure of 10 ± 1 kN at an air 
temperature of 24 °C and an air relative humidity of 45%.  The crushing strength of the 
tablets was investigated with a Heberlein apparatus (Flisa, Le Locle, Switzerland). The 
geometrical parameters were measured with a screw micrometer (Mitutoyo, Japan). The 
weight of the tablets was calibrated to 60 mg. Each tablet contained 15 mg of ME and 45 
mg of PEG 4000. 
 
Dropping method 
 For the preparation of the Levodopa-PEG 4000 solid dispersion by dropping 
method, PEG 4000 was weighed and melted in a double-layered beaker at 58 °C (± 1 °C) 
and a measured amount of Levodopa was added and stirred. The measured amounts of 
Levodopa and PEG 4000 corresponded to a drug-carrier ratio of 1:3 (each solid drop 
contained 5 mg of Levodopa and 15 mg of PEG 4000). The melted drug-carrier mixture 
was pipetted and placed into an adjustable heating device to keep the temperature 
constant. The melted drug-carrier mixture was dropped onto a stainless steel plate, where 
it solidified into round particles. The surface free energy of the plate was 29.73 mN/m. 
The temperature of the stainless steel plate was 20 °C (± 1 °C). Three round particles (60 
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mg) were placed into hard gelatin capsules (size no. 2) for further investigations. For this 
purpose an special equipment developed by Bülau and Ulrich were used (Fig. 1.) 
 
 
 
Fig. 1. Equipment used for dropping method with solid drops 
 
For the preparation of the ME - PEG 4000 solid dispersion by the dropping 
method, PEG 4000 was weighed and melted in a double-layered beaker at 58 °C (± 1 °C) 
and a measured amount of ME was added and stirred. The measured amounts of ME and 
PEG 4000 corresponded to a drug - carrier ratio of 1:3 (each solid drop contained 5 mg of 
ME and 15 mg of PEG 4000). The melted drug - carrier mixture was pipetted and placed 
into an adjustable heating device to keep the temperature constant. The melted drug - 
carrier mixture was dropped onto a stainless steel plate, where it solidified into round 
particles. The temperature of the stainless steel plate was 20 °C (± 1 °C). Three round 
particles (60 mg) were placed into hard gelatin capsules (size no. 2) for further 
investigations. 
 
In vitro dissolution studies 
 Samples of conventional, direct capsule filling and dropping method containing 
Levodopa were prepared for dissolution studies. Samples were filled into hard gelatin 
capsules (size no. 2). Each capsule contained 15 mg of Levodopa and 45 mg of PEG 
4000. Dissolution tests were performed with a Pharmatest (Hainburg, Germany) 
dissolution tester, set with a paddle speed of 100 rpm. Artificial enteric juice (900 ml) 
with a pH of 7.5 (± 0.1) at 37 °C (± 0.5 °C) was used. Samples were withdrawn at 5, 10, 
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20, 30 and 60 minutes, and were assayed spectrophotometrically at 280 nm (Helios α, 
Spectronic Unicam, Cambridge, UK) after filtering. 
 Dissolution studies for samples containing ME were carried out as follow: 
Samples of tablets, physical mixture, pure ME and round particles were prepared for 
dissolution studies. The physical mixture, round particles and pure ME as reference 
sample were filled into hard gelatin capsules (size no. 2). Each capsule contained 15 mg 
of ME and 45 mg of PEG 4000. Dissolution tests were performed with a Pharmatest 
(Hainburg, Germany) dissolution tester, set with a paddle speed of 100 rpm. Artificial 
enteric juice (900 ml) with a pH of 7.5 (± 0.1) at 37 °C (± 0.5 °C) was used. Samples 
were withdrawn at 5, 10, 20, 30, 60 and 90 min, and were assayed spectrophotometrically 
at 361 nm (Helios α, Spectronic Unicam, Cambridge, UK) after filtering. 
 
Differential scanning calorimetry (DSC) 
 Thermal analysis was carried out with a DSC instrument (Mettler-Toledo GmbH, 
Switzerland). Sample was weighed into a non-hermetically sealed aluminum pan. The 
samples were heated from 25 to 400 °C at a heating rate of 5 °C/min for Levodopa. In 
case of ME the samples were heated from 25 to 300 °C at a heating rate of 5 °C/min and 
30 °C/min. The instrument was calibrated by using indium. 
 
X-ray powder diffractometry (XRPD) 
 XRPD was performed with a Philips X-ray diffractometer (PW 1050/70 PW 
1710). The measurement conditions were: radiation source: CuKα, scan speed (2θ/s): 
0.035, step size (2θ/s): 0.035, time per step: 1.0.s. 
 
Investigation of particle size 
The particle size distribution of the ME was measured by laser diffraction 
(Malvern Mastersizer 2000, Malvern Ltd., Worcestershire, UK). For the measurements, 
the samples were dispersed in air and deagglomerated at an air pressure of 1 bar. The 
particle size was determined in the range 0.02-2000 µm and the measurements were 
repeated three times. The particle size of the product obtained with the dropping method 
(S3) was determined with a screw micrometer (Mitutoyo, Japan). 
 
Kinetic calculation by Langenbucher 
The dissolution profiles of samples and pure ME can be described by modified 
Langenbucher model (Langenbucher, 1976). 
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where m0, the mass of the drug at time t=0 and mt, at time t. The linear transformation 
resulted in the rate constant (k value) and the intercept value (n). 
 
Chemometric method 
Fiala developed a procedure, correlation analysis, for the XRPD analysis of 
mixtures of components. Nassab et al. introduced a multivariate curve resolution method 
for the same purpose, but without reference to the Joint Committee on Powder Diffraction 
Standards (JCPDS). The chemometric method of multivariate curve resolution with 
alternative least squares (MCR-ALS) can break the data matrix down into profiles 
(composition profiles and pure diffractogram profiles) with the use of certain constraints. 
Unfortunately, this decomposition is very often not unique because of the rotational and 
intensity (scaling) ambiguities. The rotational ambiguities can be moderated or even 
eliminated if convenient constraints can be used. 
The self - modeling curve resolution (SMCR) method, one of the oldest 
chemometric procedures, was introduced for two-component systems by Lawton and 
Sylvestre to deconvolve raw spectroscopic data into the product of two physically 
interpretable profile matrices provided that both concentrations and absorbances are non-
negative, accepting both as minimal constraints. Unfortunately, the solution is not unique: 
the method can give feasible regions only for the pure component profiles without further 
restrictions. Borgen et al. generalized the LS method for three-component systems with 
the same minimal constraints. Rajkó et al. recently revisited Borgen’s method, gave a 
clearer interpretation and used computational geometry tools to find inner and outer 
polygons. We will introduce the SMCR method to evaluate XRPD data in for Meloxicam 
investigations. 
 
Determination of surface free energy 
 The product shape is influenced by the surface free energy of the cooling surface 
in the melt solidification technology. The surface free energy can be calculated from the 
contact angles between the surface and test liquids and contact angles can be determined 
with Drop Shape Analyzers. Figure 2. Shows contact angles of water on different 
surfaces. 
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water on glass water on teflon water on steel 
 
Fig. 2. Contact angles of water on different surfaces 
 
4. Results and discussion 
Melt solidification technology requires a surface with moderate surface free 
energy. In the case of high surface free energy the melt drop may become deformed 
during solidification, and on a surface with low surface free energy the drop may flow 
before solidification as a round particle. Consequently, our choice fell on steel surface to 
produce spherical particles with special hot melt technology. 
 
Results of preformulation studies using Levodopa 
Preformulation studies were carried out to determine the most suitable ratio of the 
Levodopa-PEG 4000 mixture. The sample involving a drug-carrier ratio of 1:3 with PEG 
4000 as carrier exhibited the best drug release properties. 
Solid dispersions of Levodopa-PEG 4000 were prepared by conventional method (series 
3), direct capsule filling method (series 2) and dropping method (series 1) to compare 
their dissolution rates. The results of the dissolution tests show that the solid dispersions 
made by the dropping method have better drug release properties than those produced by 
the other to methods, particularly during the first 20 minutes (Fig. 3). Another aspect of 
preformulation studies was to investigate the applicability of the dropping method to 
produce spherical particles. 
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Fig. 3. Comparison of dissolution rates of solid dispersions produced by three methods. ■ Series 1: samples 
made by dropping method. ♦ Series 2: samples made by direct capsule filling method. ▲ Series 3: samples 
made by conventional method 
 
Result of the DSC investigation of pure levodopa shows the decomposition prior 
to melting at 281 °C. In case of the samples, which contain PEG 4000 the decomposition 
stage is shifted to 370 °C. On the other hand, in case of samples where Levodopa was 
added to the melted PEG 4000 lower energy is required to initialize the melting process 
of the levodopa. This means that part of the levodopa crystals were dissolved or 
converted to a new crystal in presence of melted PEG 4000, which results in better 
dissolution properties. 
Better dissolution rate of round particles than samples made by direct capsule 
filling method is also influenced by its bigger surface area and lack of the plaque, which 
may occur in case of direct capsule filling method. 
 
Structural changes of Levodopa crystals in different samples were investigated by 
XRPD. XRPD investigation shows that Levodopa crystals were changed when blended 
with PEG 4000. Some of the peaks appeared in the diffractogram of pure levodopa 
disappeared in diffractograms of the samples where levodopa was blended with PEG 
4000. Furthermore, samples prepared by dropping method show fewer peaks than the 
samples prepared by physical mixture. Results of XRPD investigation show that the 
crystallinity of the Levodopa decreases by blending in melted PEG 4000. This changes of 
the crystals promotes the solubility of the Levodopa. 
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Results and discussions for Meloxicam 
 The particle size distribution of ME is important as concerns the 
wettability properties and dissolution: the relatively small particle size of ME promotes its 
dissolution rate when it is blended with PEG 4000. For the development of the product, 
micronized ME was chosen because of its ideal particle size and specific surface. The 
particle size distribution of ME at D 90% was 5.97 µm (STDEV ± 0.31) and at D 10% 
was 0.73 µm (STDEV ± 0.01). 
Preformulation studies were carried out to determine the most suitable ratio of the 
drug - carrier mixture. The sample involving a drug - carrier ratio of 1:3 with PEG 4000 
as carrier exhibited the best drug release properties. 
 Tablets (as the most frequently used dosage form), physical mixtures and round 
particles (solid drops) were compared with the pure drug in order to determine and 
compare the drug - release properties. 
 The rates of dissolution of the above - mentioned three samples and pure drug 
were measured and are shown in Figure 4, which demonstrates that all three samples 
dissolved faster than the pure drug and there was a significant increase in the rate of 
dissolution of the sample made by the dropping method (S3). 
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Fig. 4. Rates of dissolution of different samples. Ref.: pure ME, S1: physical mixture, S2: tablet, S3: round 
particles developed by dropping method 
  
Further examinations (DSC, XRPD and chemometric analyses) were carried out to 
find out why samples made by the dropping method had better dissolution properties than 
the other samples. 
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The DSC method was used to determine the physical-chemical properties of ME 
and the binary systems (physical mixture and round particles). The thermogram of ME 
exhibited a sharp endothermic peak at 260 °C, corresponding to the melting point of ME. 
In the sample (S1 and S3) where PEG 4000 was present, the peak was about 62 °C for 
PEG 4000 and 219 °C for ME due to the partly dissolving of ME in the melted PEG 4000 
(Fig. 5). This phenomenon appeared in the dropping method too, where ME was added to 
melted PEG 4000. In the cases of the tablets and physical mixture, no heat was applied, 
so there was no possibility for ME to dissolve in PEG 4000. This might be one of the 
reasons why the samples formulated by the dropping method exhibited better dissolution 
than the tablets and physical mixtures. 
 
Fig. 5. DSC curves of pure ME, physical mixture (S1) and round particles made by the dropping method 
(S3) at heating rate of 5 °C/min 
  
X-ray powder diffraction was used to investigate the starting materials ME, PEG 
4000a (untreated, commercial) and PEG 4000b (melted and solidified) and also the 
sample made by the dropping method (S3) and the physical mixture (S1) (Fig. 6). Visual 
inspection did not reveal any significant difference in crystal structure, i.e. the 
diffractograms of the physical mixture and the particles made by the dropping method 
seemed to be very similar. The diffractograms of S1 and S3 displayed the characteristic 
values of the starting materials. It is clear that, in the case of S3, the crystals of ME that 
dissolved in the melted PEG 4000 recrystallized during cooling. The round particles 
contained the recrystallized ME in suspended form. Consequently, the DSC and XRPD 
studies demonstrated the stable crystalline form of ME in S3 and the absence of any well 
defined ME - PEG 4000 interaction. 
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Fig. 6. X-ray powder diffraction. Starting material: ME (pure), PEG 4000a (untreated, commercial) and PEG 
4000b (melted and solidified). Samples: S1 - physical mixture (ME - PEG PM), S3 - round particle (ME - 
PEG dropping) 
 
The question arose of whether the fast and quantitative dissolution of ME from S3 
can be explained only in terms of the melt technology and/or the homogeneous 
distribution of ME in the solid dispersion. To investigate this, a chemometric method, 
SMCR, was used. Based on the three components given by the SMCR method, the bands 
of the diffractograms indicate PEG 4000, ME and a new (mixed) crystal form. The 
estimated bands for the compositions of the samples were first calculated via the 
unconstrained SMCR method. Constraints can be applied to make bands as narrow as 
possible. The ME content in the PEG 4000 sample is zero or near to zero, the PEG 4000 
content in the ME sample is zero, and the new mixed crystal form content in the ME and 
PEG 4000 samples is zero or as little as possible. It can be concluded that the content of 
the new mixed crystal form is smaller in the physical mixture, while both the PEG 4000 
and ME contents are decreased in the round particles made by the dropping method, and 
additionally the content of the new crystal form is increased. The explanation is as follow; 
The SMCR calculation indicated a small amount of the new mixed crystal form in the 
physical mixture (S1). This suggests rearrangement of ME and PEG 4000 in the binary 
system because of the mechanical effects (mixing, friction and heat). The melt technology 
naturally results in a greater change in the structure of the binary system, with the 
appearance of the new mixed crystal form. 
This is connected with the partial dissolution of the ME in the melted PEG 4000 
and the fast solidification of the drops. Some of the dissolved ME return to the original 
state after solidification, while the remainder of the ME, in the form of molecule-clusters, 
is incorporated in the macromolecules of PEG 4000. This interaction between ME and 
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PEG 4000 does not give a different appearance to the X-ray diffractogram because of the 
overlapping of the characteristic values, but the chemometric method demonstrated the 
presence of the new mixed crystal form, which resulted in fast and quantitative 
dissolution from the solid dispersion of S3. 
 
5. Summary 
 The aim of my PhD work was to adopt a new technology to increase the 
bioavailability of the poorly water-soluble drugs and to prepare a solid dosage form using 
dropping method which is a special hot melt technology. By this method solid dosage 
form can be produced by a single step process, which, simplifies the manufacturing 
process. The role of the applied technology to increase the drug release properties of the 
poorly water-soluble drugs was in focus as well as the carriers. 
 For this purpose Levodopa and Meloxicam as poorly water-soluble compounds 
were selected and two sets of investigations were applied separately with same 
conditions. 
 The production of the spherical particles by dropping method was in Germany, at 
the Institute of Process Engineering of Martin Luther University, Halle-Wittenberg. 
 Levodopa as a poorly water-soluble drug was used at first set of experiments for 
preformulation studies. Different carriers and their combination with different drug-
carrier ratio were used to increase the dissolution rate of the levodopa. Best result were 
achieved when levodopa were added to PEG 4000 with 1:3 drug-carrier ratio and this was 
the most suitable carrier to produce spherical particles by dropping method. Results of the 
preformulation studies show that samples prepared by dropping method had better 
dissolution properties than the others. On the other hand the process of production were 
simplified and the products were prepared by a single (dropping) step without any need 
for further processing. 
 Promising results from preformulation studies encouraged us to apply the 
dropping method with another poorly water-soluble drug and to apply more investigations 
for better understanding of this new technology. For this purpose Meloxicam a poorly 
water-soluble drug were used for second set of experiments. Samples of Meloxicam-PEG 
4000 solid dispersions were prepared according to protocol developed by preformulation 
studies of Levodopa-PEG 4000 (Fig. 7). 
 
 
 
 
 14
 
Protocol of dropping method 
 
Carrier (investigation of physical and chemical properties) 
 
Heating process 
 
Drug material (investigation of physical and chemical properties) 
 
Blending (homogeneous dispersion of dissolved or 
suspension form) 
 
Dropping method 
 
Choosing surface and its temperature 
 
Solid product (spherical particles) 
 
 
Intermediate product 
 
 
Final product capsulation 
 
Fig. 7. Formulation of solid dispersion by dropping method 
 
Wider investigations and tests were applied on Meloxicam-PEG 4000 samples after 
achieving the similar good results as preformulation studies. Physical and chemical tests 
were applied to investigate the behavior of the Meloxicam and PEG 4000 crystals. Such 
investigations (DSC, XRPD, Chemometric, Dissolution test) showed that the better 
solubility of the samples prepared by dropping method (spherical particles) is the result of 
the applied technology. The reason for increased solubility characteristic of samples 
prepared by dropping method can be explained with partial dissolution of the poorly 
water-soluble drug in water-soluble carrier (solid dispersion) and formation of the new 
drug-carrier crystals (solid solution), which, investigated by chemometric, analyzes. It can 
concluded that: 
• Dropping method is an applicable method for preparation of solid dispersions. 
• Dropping method can increase the bioavailability of the poorly water-soluble 
drugs. 
• The process of production can be simplified. 
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